Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-05-10
2005-05-10
Winkler, Ulrike (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093200, C424S093600, C424S233100, C435S005000, C435S069100, C435S070100, C435S320100, C435S325000, C435S455000, C435S476000
Reexamination Certificate
active
06890528
ABSTRACT:
The present invention relates to cells for the production of helper dependent adenoviral vectors, including at least the following genic units: a first genic unit comprising an adenovirus defective genome having the inverted terminal repeats in head-to-tail configuration, the encapsidation signal inactivated, and at least one of the non-structural regions inactivated; a second genic unit comprising at least one inducible promoter and at least one of the regions inactivated in the first genic unit, said regions being under the control of said inducible promoter; whereby following the activation of the inducible promoter of the second genic unit and the infection of the cells with said helper dependent adenoviral vectors, the first genic unit and the second genic unit enable the production of said helper dependent adenoviral vectors in said cells in absence of helper vector.
REFERENCES:
patent: 5948675 (1999-09-01), Klatzmann et al.
patent: 2 738 575 (1997-03-01), None
patent: WO9522617 (1995-08-01), None
patent: WO9732481 (1997-09-01), None
patent: 9813499 (1998-04-01), None
patent: 9813510 (1998-04-01), None
patent: 0012740 (2000-03-01), None
Alemany et al. Complementation of helper-dependent adenoviral vectors:size effects and titer fluctuations. Journal of Virological Methods (1997) vol. 68, pp. 147-159.*
Yeh et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from 293-derived cell line expressing a minimal E4 functional unit. Journal of Virology (1996) vol. 70, No. 1, pp. 559-565.*
GeneBank # AF083132; M73260; J01917.*
Tuboly et al. Restriction endonuclease analysis and physical mapping of the genome of porcine adenovirus type 5. Virus Research (1995) vol. 37, No. 1, pp. 49-54.*
Baron, U. et al. “Co-regulation of two gene activities by tetracycline via a bidirectional promoter”, Nucleic Acids Research, 1995, vol. 23, pp. 3605-3606.
Brough, D. et al. “A Gene Tranfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4”, Journal of Virology, 1996, vol. 70, pp. 6497-6501.
Bett, A. et al. “An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3”, Proc. Natl. Sci. USA, 1994, vol. 91, pp. 8802-8806.
Calos, M. “The potential of extrachromosomal replicating vectros for gene therapy”, TIG, 1996, vol. 12, pp. 463-466.
Calos, M. “Stability without a centromere”. Proc. Natl. Acad. Sci. USA, 1998, vol. 95, pp. 4084-4085.
Deuschle, U. et al. “Tetracycline-Reversible Silencing of Eukaryotic Promoters”, Molecular and Cellular Biology, 1995, vol. 15, pp. 1907-1914.
Engelhardt, J. et al. “Ablation ofE2Ain recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver”, Proc. Natl. Acad. Sci. USA, 1994, vol. 91, pp. 6196-6200.
Freundlieb, S. et al. “A Tetracycline Controlled Activation/Repression System with Increased Potential for Gene Transfer into Mammalian Cells”, The Journal of Gene Medicine, 1999, vol. 1, pp. 4-12.
Gossen, M. et al. “Transcriptional Activation by Tetracyclines in Mammalian Cells”, Science, 1995, vol. 268, pp. 1766-1769.
Hitt, M. et al. “Techniques for Human Adenovirus Vector Construction and Characterization”, Methods in Molecular Genetics, 1995, vol. 7, pp. 13-30.
Hitt, M. et al. “Human Adenovirus Vectors for Gene Tranfer into Mammalian Cells”, Advances in Pharmacology, 1997, vol. 40, pp. 137-206.
Kozarsky, K. et al. “In VivoCorrection of Low Density Lipoprotein Receptor Deficiency in the Wantanabe Heritable Hyperlipidemic Rabbit with Recombinant Adenoviruses”, The Journal of Biological Chemistry, 1994, vol. 269, pp. 13695-13702.
Krougliak, V. et al. “Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants”, Human Gene Therapy, 1995, vol. 6, pp. 1575-1586.
No, D. et al. “Ecdysone-inducible gene expression in mammalian cells and transgenic mice”, Proc. Natl. Acad. Sci. USA, 1996, vol. 93, pp. 3346-3351.
Parks, R. et al. “A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal”, Proc. Natl. Acad. Sci. USA, 1996, vol. 93, pp. 13565-13570.
Spencer, D. et al. “Conrolling Signal Transduction with Synthetic Ligands”, Science, 1993, vol. 262, pp. 1019-1024.
Wang, Y. et al. “A regulatory system for use in gene transfer”, Proc. Natl. Acad. Sci. USA, 1994, vol. 91, pp. 8180-8184.
Yang, Y. et al. “Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy”, Proc. Natl. Acad. Sci. USA, 1994, vol. 91, pp. 4407-4411.
Amalfitano, A. et al. “Production and Characterization of Improved Adenovirus Vectros with the E1, E2b, and E3 Genes Deleted”, Journal of Virology, 1998, vol. 72, pp. 926-933.
Dedieu, J. et al. “Long-Term Gene Delivery into the Livers of Immunocompetent Mice with E1/E4-Defective Adenoviruses”, Journal of Virology, 1997, vol. 71, pp. 4626-4637.
Gorziglia, M. et al. “Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy”, Journal of Virology, 1996, vol. 70, pp. 4173-4178.
Gao, G. et al. “Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy”, Journal of Virology, 1996, vol. 70, pp. 8934-8943.
Recchia, A. et al. “Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector”, Proc. Natl. Acad. Sci. USA, 1999, vol. 96, pp. 2615-2620.
Rittner, K. et al. “Conditional Repression of the E2 Transcription Unit in E1-E3-Deleted Adenovirus Vectos is Correlated with a Strong Reduction in Viral DNA Replication and Late Gene Expression In Vitro”, Journal of Virology, 1997, vol. 71, pp. 3307-3311.
Zhang, Y et al. “A new logic for DNA engineering using recombination inEscherichia coli”, Nature Genetics, 1998, vol. 20, pp. 123-128.
Ginkel Laura M.
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
Tribble Jack L.
Winkler Ulrike
LandOfFree
Cells for the production of helper dependent adenoviral vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cells for the production of helper dependent adenoviral vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cells for the production of helper dependent adenoviral vectors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3438126